Dr. John Cush RheumNow
5 years 3 months ago
Therapeutic Drug Monitoring for Infliximab: Might it Actually Work?
https://t.co/Onl6cijKbb https://t.co/jnwx4ZZvhz
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. John Cush RheumNow
5 years 3 months ago
Ten Things to Tell Patients About Diet and Rheumatic Disease
https://t.co/DpBAJwCJCY https://t.co/AVlgHfdP08
Dr. John Cush RheumNow
5 years 3 months ago
With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with RA are treated with a modified T2T
approach, superior outcomes can be anticipated.
Read on:
https://t.co/sV5hJRzPJW https://t.co/ADppVd3CmZ
A study of rheumatologists in Ontario, Canada has shown an increasing percentage of women in rheumatology; unfortunately they have lower salaries but see fewer patients than do their older, male colleagues.
Between 2000 to 2015 the number of full time rheumatologists increased from 89 to 120, with the percentage of females increasing from 27.0% to 41.7%.
Dr. John Cush RheumNow
5 years 3 months ago
The ACR has released an updated position statement on patient safety and site of service for biological.
https://t.co/NONozoIIq6 https://t.co/CSbSuXBb8n
Dr. John Cush RheumNow
5 years 3 months ago
Health care utilization by knee OA pts varies. In nearly 1 million Knee OA (Medicare), 33% ended up with TKR. TKR/arthroplasty assoc w/ more clinic visits; PT, specialist care & intraarticular Rx assoc. w/ less TKR. TKR range 26% to 42% by region https://t.co/d1EQTTie8X
Dr. John Cush RheumNow
5 years 3 months ago
CDC: as of 5/15/2021; the rates of flu test positivity was 0.051-0.18% for the 2020-21 flu season - compared to usual rate of 10%-19% before COVID. Actual influenza hospitalizations dropped from 44.2 to 0.8/100 000 population https://t.co/N8b1sQWWIh
Dr. John Cush RheumNow
5 years 3 months ago
Higher rate of Parkinsonism in Osteoarthritis? Taiwan Health Insurance claims analysis of 33,360 OA pts (age 50-64 yrs) vs age matched non-OA - found incr risk of Parkinsons in OA pts (aHR=1.41), esp in knee or hip OA (aHR 1.55) group. https://t.co/SHudF5NnwH
Neuropsychiatric (NP-SLE) or CNS lupus events range from mild to severe; several recent studies have noted that NPS lupus is common and should be screened for.
A metanalysis of the literature finds 22 studies wherein the mean frequency of NPSLE ranged from 10.6% to 96.4%. When researchers with the Swiss SLE cohort study looked at their population, NPSLE was found in 28.1%. This included cerebrovascular insults, seizures and
Dr. John Cush RheumNow
5 years 3 months ago
Stroke risk is increased in arthritis (RR 1.36, 95% CI: 1.27–1.46); esp for RA (RR 1.38), AS (RR 1.49), PsA (1.33) & gout (1.40); but NOT osteoarthritis (RR=1.03). Apparently Inflammation drives this risk. https://t.co/Snb6OrtZJH
The American College of Rheumatology (ACR) has issued new guidelines on the treatment of rheumatoid arthritis, addressing questions about initial treatment with methotrexate and minimizing reliance on glucocorticoids. Use of these medications in specific high-risk populations also was included.
Dr. John Cush RheumNow
5 years 3 months ago
Global metanalysis of 67 studies of T2T in gout shows only 34% on ULT achieve a serum urate target. Thus only a minority of gout receive T2T care worldwide. Thos on ULT, have low rates of continuous Rx, SUA testing, & achieving SUA target https://t.co/zpBRhRaek5
Dr. John Cush RheumNow
5 years 3 months ago
BRAVE-AA1 - a Phase 2 trial of 110 pts w/ Alopecia areata Rx w/ either PBO or baricitinib (1, 2, 4 mg); showed significantly greater improvement with Bari 2-mg (33.3%, P = .016) and 4-mg (51.9%, P = .001) versus placebo (3.6%). https://t.co/tzDeb4l60H
